Please assess the completion status of the following clinical trial:

Trial Title: Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 22.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Genotype 2 or 3 HCV-infection or Genotype 1, serum HCV RNA ≥ 50,000 IU/mL~* Not co-infected with HIV~* Use of highly effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* History of any other clinically significant chronic liver disease~* Pregnant or nursing female or male with pregnant female partner~* History of significant drug allergy to nucleoside/nucleotide analogs.~* Participation in a clinical study within 3 months prior to first dose~* Positive result for significant drug use at Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: SOF+RBV 12 wk: GT 2 or 3, TN (Type: EXPERIMENTAL): Treatment-naive (TN) participants with genotype (GT) 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
- Group 2: SOF+RBV 12 wk+PEG 4 wk: GT 2 or 3, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 4 weeks.
- Group 3: SOF+RBV 12 wk+PEG 8 wk: GT 2 or 3, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 8 weeks.
- Group 4: SOF+RBV+PEG 12 wk: GT 2 or 3, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily+weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 12 weeks.
- Group 5: SOF 12 wk: GT 2 or 3, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily for 12 weeks.
- Group 6: SOF+RBV+PEG 8 wk: GT 2 or 3, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 8 weeks.
- Group 7: SOF+RBV 12 wk: GT 1, TE (Type: EXPERIMENTAL): Treatment-experienced (TE) participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
- Group 8: SOF+RBV 12 wk: GT 1, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
- Group 9: SOF+RBV 12 wk: GT 2 or 3, TE (Type: EXPERIMENTAL): Treatment-experienced participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
- Group 10: SOF+RBV 8 wk: GT 2 or 3, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 8 weeks.
- Group 11: SOF+RBV 12 wk: GT 2 or 3, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus split-dose RBV (800 mg in a divided daily dose) for 12 weeks.
- Group 12: SOF+RBV+LDV 12 wk: GT 1, TE (Type: EXPERIMENTAL): Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
- Group 13: SOF+RBV+LDV 12 wk: GT 1, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
- Group 14: SOF+RBV+GS-9669 12 wk: GT 1, TE (Type: EXPERIMENTAL): Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
- Group 15: SOF+RBV+GS-9669 12 wk: GT 1, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
- Group 16: LDV/SOF FDC 12 wk: GT 1, fibrosis (Type: EXPERIMENTAL): Treatment-experienced participants with genotype 1 HCV infection and Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
- Group 17: LDV/SOF FDC+RBV 12 wk: GT 1, fibrosis (Type: EXPERIMENTAL): Treatment-experienced participants with genotype 1 HCV infection with Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
- Group 18: LDV/SOF FDC 12 wk: GT 2 or 3, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
- Group 19: LDV/SOF FDC 12 wk: GT 2 or 3, TE (Type: EXPERIMENTAL): Treatment-experienced participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
- Group 20: LDV/SOF FDC+RBV 12 wk: GT 1, hemophiliac (Type: EXPERIMENTAL): Hemophiliac participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
- Group 21: LDV/SOF FDC+RBV 6 wk: GT 1, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 6 weeks.
- Group 22: LDV/SOF FDC 6 wk: GT 1, TN (Type: EXPERIMENTAL): Treatment-naive participants with genotype 1 HCV infection were randomized to receive LDV 90 mg/SOF 400 mg FDC once daily for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete